We are excited to exhibit at ENA 2026 from November 18th - 20th in Barcelona, Spain. The event will highlight the latest findings from preclinical research and phase I studies, with internationally recognized speakers sharing insights across a range of engaging session formats designed to spark discussion and support professional growth. Come meet our team at Booth #9 to explore Biocytogen’s extensive portfolio of target-humanized and disease mouse models supporting oncology target validation, in vivo efficacy and safety evaluation across immunotherapies, ADCs, and targeted protein degraders, alongside our AI-powered antibody discovery platform.
What is ENA 2026?
The EORTC-NCI-AACR (ENA) Symposium is a leading conference on molecular targets and cancer. It brings together the global community of drug development and translational research professionals to explore the latest breakthroughs in molecular biology, target identification and drug innovation.
Event Overview
Date: November 18th - 20th, 2026
Venue: International Barcelona Convention Center, Plaça de Willy Brandt, 11-14, Sant Martí, 08019 Barcelona, Spain
Booth: 9
Posters
The B-hCRBN Mice Model Facilitates PROTACs Studies Base on CRBN Ligands
Utilizing a Humanized CD8 Mouse Model for Non-clinical Studies of Cancer Immunotherapy
BCG024: A Novel DLL3xCD3x4-1BB Trispecific T Cell Engager Enhances T Cell Persistence and Functionality in Preclinical Models
BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.